All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 7 read as filed from the record and 2 are SI estimates, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
1 warning event since 2018; the latest 2024-04-30.
From the record
111, Inc.'s filings since 2018 show 1 warning event: a late-report notice (Form NT 10-K or NT 10-Q, the latest 2024-04-30) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
+34.5% a year over 10 filed years; profitable in 0 of 10.
From the record
111, Inc.'s 10 filed years say what it did: revenue went from CNY 874 million in fiscal 2016 to CNY 13 billion in fiscal 2025, up 34.5% a year; it rose in 7 of 9 years; the deepest fall was 16% from fiscal 2023 to fiscal 2025; net income was positive in 0 of 10 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 4.4/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: 111, Inc.'s shareholder treatment is put at 4.4 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 44% of 18 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
Leverage 133%: owes 133¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, 111, Inc.'s shareholders' equity was below zero, so the profit on it is not read, and gross profitability: its products earned about 33 cents per dollar of everything the company owns. Leverage: it owed about 133 cents per dollar of assets, and net share issuance: its share count grew 1.3% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
bottom 42% of 18 in its family; net margin -0.2%.
From the record
111, Inc.'s standing among 18 graded names in its industry family: revenue of CNY 13 billion in fiscal 2025 is not ranked by size, since the family reports in another currency; a net margin of -0.2% ranks in the bottom 42%; revenue growth of -2.4% a year over the last 3 filed years ranks in the bottom 42% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
SI estimate 7.2/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: 111, Inc.'s leadership is put at 7.2 of 10 with a confidence of 35 of 100, because read from one part only, the median years the people in charge have been filing, which ranks in the top 28% of 12 in its family; it files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they set up to do next?
How much room does it have to grow?
bottom 44% of 18 in its family for room to expand.
From the record
111, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of CNY 561 million against no long-term debt tagged leaves 25.5% of its assets as net cash, top 25% of its family; cash from operations less capital spending is 0.9% of revenue (bottom 47%); a gross margin of 5.8% (bottom 9%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
bottom 18% of 16 in its family for growth drivers.
From the record
111, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew -2.4% a year over the last three filed years against 34.5% over all 10, slowing (bottom 9% of its family); the newest year grew -12.8% (bottom 22%); capital spending grew -47.9% a year (bottom 22%) (its annual reports). 111, Inc. reported 7 product lines in fiscal 2025: Drugs at CNY 12 billion (92%), Nutritional Supplements at CNY 435 million (3%), Business to Consumer B2c Business at CNY 223 million (2%), and 4 more; 1 of 7 grew against the year before (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
top 43% of 15 in its family for expectations against reality.
From the record
111, Inc.'s newest year against its own record: revenue of CNY 13 billion in fiscal 2025 came in 15.5% below the CNY 15 billion its prior three years' pace pointed to (bottom 17% of its family); net income of CNY 23 million against a prior three-year average of CNY 250 million (top 17%); a net margin of -0.2% against -1.8% before (top 30%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made